The mission of the Cancer Epidemiology Program is to facilitate the conduct of epidemiological research and translation of those findings into prevention strategies to reduce the burden of cancer. A key goal of the Program is the integration of cancer epidemiology research across DF/HCC's clinical-based and discipline- based programs. The Program also is deeply invested in the mission of the training and mentoring of students and postdoctoral and clinical fellows that represent the next generation of cancer epidemiologists. To achieve these goals, the specific aims of the Program are to accelerate science, collaboration, translation and training of its members, in the following areas of research: (1) Primary and secondary precision cancer prevention; (2) Next-generation genomic epidemiology of cancer; (3) Epidemiological studies of metabolism and cancer; and (4) Epidemiological studies of cancer survivorship. The program has 71 members, representing six DF/HCC institutions and 14 academic departments. In 2014 peer-reviewed grant funding attributed to the Program was $22.6 million in total costs from the NCI and $2.3 million from other sponsors. During the current funding period, Cancer Epidemiology Program members published 1,417 cancer-relevant papers. Of these 41% were inter-institutional, 41% were intra-programmatic and 31% were inter-programmatic collaborations between two or more DF/HCC members. Overall, when counted once, 27% of DF/HCC publications were inter- programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-54
Application #
9614961
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
54
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications